Adgyl Lifesciences offers comprehensive range of in vivo services to support Discovery, Preclinical and Early to late stage development of novel molecules with non-clinical IND track and NDA enabling safety assessment studies for global regulatory registrations. With 30+ years of GLP experience, we ensure reliability and accuracy of data with the highest level of quality and customer satisfaction. With specialized facilities and a wealth of experience, we offer services for diverse industries - biotech, pharmaceuticals, biologics, medical devices, agrochemicals, cosmetics, nutraceuticals, animal health products, specialty chemicals and industrial chemicals. Our team has supported 90+ end-to-end IND enabling packages, 65+ Carcinogenicity studies, 10,000+ regulatory studies. With our strategic partner we support GLP studies in Analytical R&D and ecotoxicology. Our facility is GLP, AAALAC, OLAW and SAM certified. Our team is well versed with all study guidelines prescribed by international regulatory agencies; including but not limited to US-FDA, OECD, EMA, MHRA, HSA, WHO, DCGI, DBT and CIB of India.